31Jul 2023
Oncological outcomes of concurrent chemoradiotherapy with docetaxel, cisplatin, and 5‐fluorouracil for locally advanced squamous cell carcinoma of the external auditory canal: A single‐center study

Oncological outcomes of concurrent chemoradiotherapy with docetaxel, cisplatin, and 5‐fluorouracil for locally advanced squamous cell carcinoma of the external auditory canal: A single‐center study

The study found that TPF‐CCRT (concomitant chemoradiotherapy with docetaxel, cisplatin, and 5‐fluorouracil) showed promise in treating advanced squamous cell carcinoma of the external auditory canal (EACSCC). Among the 35 patients with T3 and T4 stage disease, the 5-year overall survival rates were 100% for T3 and 64.2% for T4. Notably, the survival rate was significantly higher for T4a (82.4%) compared to T4b (30%). The 5-year progression-free survival rates were 100% for T3, 68% for T4a, and 20% for T4b.

  • #ent

Like

Save

Share